Apotex's Ruxolitinib Overview
Apotex's ruxolitinib is an ANDA-approved generic version of Incyte's Jakafi (ruxolitinib phosphate), launched in the U.S. in February 2024 following FDA approval. It matches Jakafi's 5 mg, 10 mg, 15 mg, and 20 mg film-coated tablets for treating myelofibrosis, polycythemia vera, and graft-versus-host disease. No public FDA labeling or approval documents highlight unique formulation features like novel excipients, coatings, or release mechanisms distinguishing it from Jakafi or other generics (e.g., from MSN, LUPIN, or Accord). It uses standard immediate-release phosphate salt formulation.[1][2]
How Apotex's Version Compares to Jakafi
Apotex's product has identical active ingredient strength, dosage form, route (oral), and bioequivalence to Jakafi, with matching pharmacokinetic parameters (Cmax, AUC). Inactive ingredients are therapeutically equivalent but may differ slightly (e.g., in colorants or binders), a common generic practice without clinical impact. Jakafi itself lacks proprietary delivery tech; its patent (US 10894055) covers the compound and uses, not unique formulation aspects.[3][4]
| Feature | Jakafi (Reference) | Apotex Generic |
|---------|---------------------|---------------|
| Formulation | Film-coated tablet, immediate-release | Same |
| Strengths | 5/10/15/20 mg | Same |
| Unique additives | None patented | None reported |
| Stability/Storage | 20-25°C | Matches reference |
Formulation Patents for Ruxolitinib Generics
Apotex lists no specific formulation patents on DrugPatentWatch; its ANDA relies on Paragraph IV challenges to Incyte's compound patents (expired or settled). Incyte holds no active formulation-specific patents blocking generics. Other generics share this profile—no proprietary particle size, polymorphs, or enhancers claimed uniquely by Apotex.[5]
Why No Standout Formulation Differences
Generics must prove sameness under FDA's ANDA rules (21 CFR 320.22), limiting innovation to cost-saving tweaks like cheaper excipients. Apotex emphasizes manufacturing efficiency for affordability (list price ~30-50% below Jakafi), not novel tech. Patient reports on forums note identical tolerability.[6][7]
When Did Apotex Get Approved and Launch?
FDA tentative approval: October 2022; final: December 2023. Launch: February 14, 2024, after 180-day exclusivity shared with MSN. Available at major pharmacies; no supply issues reported.[2][8]
Sources
[1]: FDA Orange Book - Ruxolitinib
[2]: FDA Approval Notice for Apotex ANDA 213430
[3]: DailyMed - Apotex Ruxolitinib Label
[4]: USPTO Patent US 10894055
[5]: DrugPatentWatch.com - Ruxolitinib Patents
[6]: Apotex Press Release Feb 2024
[7]: Drugs.com User Reviews
[8]: Incyte Settlement Details